Leading global professional services firm Alvarez & Marsal (A&M) has appointed Jacques Mulder as a Managing Director in its Healthcare Industry Group to expand its biopharmaceutical and medical technology (MedTech) sector offerings. Mr. Mulder’s appointment reflects A&M’s commitment to assist clients in the biopharmaceutical and medical device industry to address multifaceted market challenges, which have been exacerbated by the Covid-19 pandemic.

With more than 25 years of leadership and consulting experience, Mr. Mulder possesses deep expertise and knowledge of the pharmaceutical and MedTech sectors. He has helped major pharmaceutical and biotechnology companies undergo strategic transformations by applying quantitative analyses, applied health economics and effective reimbursement procedures. Mr. Mulder’s significant experience complements A&M’s existing client services across the healthcare industry by bringing cutting edge strategies and innovative ideas to pharmaceutical and MedTech clients.

“Annual U.S. expenditures for drugs and medical devices exceed $500 billion per year. Newer and innovative biopharmaceuticals and medical devices will continue to provide additional and improved treatment options for patients. A&M is committed to bringing the same leadership, action and results to the biopharmaceutical and MedTech sectors that we deploy across the entire healthcare continuum,” said Martin McGahan, Managing Director and head of the firm’s Healthcare Industry Group. “Jacques’ in-depth sector knowledge and experience providing immediate operational and performance-driven solutions significantly boost A&M’s capabilities to offer integrated solutions that maximize value and drive long-term results for the pharmaceutical and device industries. Jacques’ volume-plus-value approach and outcome-driven focus are the qualities that will help our clients meet critical market demand.”

Mr. Mulder joins A&M after serving in several senior leadership positions in the U.S. and overseas. He was the Global Sector Leader for Health at EY, where he established and led its Global Health Sector. He also served as the Chief Strategy Officer of Health Care and Life Sciences at Deloitte Consulting. Most recently, he was the President of Ciox Health. Prior to these roles, Mr. Mulder served in senior leadership positions at Quintiles (now IQVIA), and as Vice President and Practice Director at The Lewin Group (then a subsidiary of Quintiles, now of Optum).